Literature DB >> 25205597

Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG).

F Zagouri1, S Peroukidis2, K Tzannis1, V Kouloulias3, A Bamias4.   

Abstract

Radical cystectomy is the treatment of choice in localized muscle-invasive urothelial cancer. Nevertheless, relapses are frequent and systemic chemotherapy has been employed in order to reduce this risk. In addition, bladder preservation strategies are appealing. During the last decade, there has been a difficulty in conducting and completing large-scale trials in urothelial cancer. This has resulted in relatively few changes in the existing guidelines. Recent studies have created renewed interest in certain fields, such as the role of chemo-radiotherapy and management of unfit patients. In addition, application of certain guidelines has been limited in everyday practice. We conducted a systematic review of the existing guidelines and recent randomized trials not included in these guidelines, and developed a treatment algorithm, regarding non-surgical therapies for non-metastatic, muscle-invasive urothelial cancer based predominantly on patients' fitness for the available therapeutic modalities.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Guidelines; Neoadjuvant chemotherapy; Radiotherapy; Urothelial cancer

Mesh:

Year:  2014        PMID: 25205597     DOI: 10.1016/j.critrevonc.2014.08.005

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  9 in total

Review 1.  Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.

Authors:  Aristotle Bamias; Bernard Escudier; Cora N Sternberg; Flora Zagouri; Athanasios Dellis; Bob Djavan; Kimon Tzannis; Loukas Kontovinis; Konstantinos Stravodimos; Athanasios Papatsoris; Dionysios Mitropoulos; Charalampos Deliveliotis; Meletios-Athanasios Dimopoulos; Constantine A Constantinides
Journal:  Oncologist       Date:  2017-06-07

2.  Performance of simultaneous high temporal resolution quantitative perfusion imaging of bladder tumors and conventional multi-phase urography using a novel free-breathing continuously acquired radial compressed-sensing MRI sequence.

Authors:  Nainesh Parikh; Justin M Ream; Hoi Cheung Zhang; Kai Tobias Block; Hersh Chandarana; Andrew B Rosenkrantz
Journal:  Magn Reson Imaging       Date:  2015-12-29       Impact factor: 2.546

3.  Metabolic coupling in urothelial bladder cancer compartments and its correlation to tumor aggressiveness.

Authors:  Julieta Afonso; Lúcio L Santos; António Morais; Teresina Amaro; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  Cell Cycle       Date:  2015-12-04       Impact factor: 4.534

4.  Design, Synthesis and Anticancer Evaluation of Fangchinoline Derivatives.

Authors:  Yazhou Liu; Bin Xia; Junjie Lan; Shengcao Hu; Lan Huang; Chao Chen; Xueyi Zeng; Huayong Lou; Changhu Lin; Weidong Pan
Journal:  Molecules       Date:  2017-11-08       Impact factor: 4.411

5.  Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression.

Authors:  Xuan-Mei Piao; Chaelin You; Young Joon Byun; Ho Won Kang; Junho Noh; Jaehyun Lee; Hee Youn Lee; Kyeong Kim; Won Tae Kim; Seok Joong Yun; Sang-Cheol Lee; Kyuho Kang; Yong-June Kim
Journal:  Int J Mol Sci       Date:  2021-11-25       Impact factor: 5.923

6.  ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.

Authors:  Ching-Chia Li; Juan-Cheng Yang; Mei-Chin Lu; Chia-Lin Lee; Chieh-Yu Peng; Wei-Yu Hsu; Yun-Hao Dai; Fang-Rong Chang; Da-Yong Zhang; Wen-Jeng Wu; Yang-Chang Wu
Journal:  Oncotarget       Date:  2016-01-12

7.  Axitinib as a third or further line of treatment in renal cancer: a single institution experience.

Authors:  G Tsironis; M Liontos; A Kyriazoglou; K Koutsoukos; A Tsiara; M Kaparelou; R Zakopoulou; A Cohen; E Skafida; S Fontara; F Zagouri; A Bamias; M A Dimopoulos
Journal:  BMC Urol       Date:  2020-06-02       Impact factor: 2.264

8.  Design, Synthesis of Novel Tetrandrine-14-l-Amino Acid and Tetrandrine-14-l-Amino Acid-Urea Derivatives as Potential Anti-Cancer Agents.

Authors:  Sheng-Cao Hu; Jin Yang; Chao Chen; Jun-Rong Song; Wei-Dong Pan
Journal:  Molecules       Date:  2020-04-09       Impact factor: 4.411

9.  Referral for "Neoadjuvant Chemotherapy" for Muscle-Invasive Bladder Cancer to a Multidisciplinary Board: Patterns, Management and Outcomes.

Authors:  Athanasios Dellis; Roubini Zakopoulou; Andromahi Kougioumtzopoulou; Kimon Tzannis; Konstantinos Koutsoukos; Charalampos Fragkoulis; Efthymios Kostouros; Athanasios Papatsoris; Ioannis Varkarakis; Konstantinos Stravodimos; Eleni Boutati; Stamata Pagoni; Miltiadis Seferlis; Michael Chrisofos; Vasilios Kouloulias; Konstantinos Ntoumas; Charalambos Deliveliotis; Constantine Constantinides; Meletios A Dimopoulos; Aristotelis Bamias
Journal:  Cancer Manag Res       Date:  2021-07-30       Impact factor: 3.989

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.